Baxter GD, et al. - Researchers aimed to evaluate the feasibility of conducting a full scale randomized controlled trial assessing the efficacy of low level laser therapy (LLLT), also known as photobiomodulation (PBM) therapy, in addition to conventional therapy, for managing breast cancer related lymphedema (BCRL). They recruited patients with BCRL from the Southern District Health Board (New Zealand) through lymphedema therapists’ referrals and randomized them into either the laser group, which received BCRL conventional therapy (e.g., wearing compression garments, massage therapy, and/or exercise) plus a 6-week LLLT (PBM) intervention program, or the control group, which received BCRL conventional therapy alone. All participants who completed LLLT (PBM) treatment said that they were satisfied with the treatment and had no serious adverse reactions. Observations thus suggested the feasibility of performing a fully powered RCT to definitively test the efficacy of the additional use of LLLT (PBM) in the management of BCRL. For such a trial, they suggest the necessity for 114 participants at baseline